IntroDuctIon
Human induced pluripotent stem cells (iPSC) derived from adult somatic cells could be used in regenerative medicine to repair tissues damaged by disease or injury. Although human iPSC have been generated from various type of somatic cells, such as skin fibroblasts 1 , keratinocytes 2 , neural stem cells (NSCs) 3 , blood cells 4, 5 and cord blood-derived endothelial cells (CBEC) 6 , scientists are still debating the best sources from which to derive iPSC. Further studies have shown that the age, origin and cell type used has a profound impact on the reprogramming efficiency as well as the quality of iPSC generation 2, 7 . A desirable protocol should aim to not only optimize all these parameters, but also to reduce both the number of factors used and the time required for reprogramming. A key observation in this regard is the recent study by Kim et al. 3 where iPSC were generated from adult NSCs by direct reprogramming with either two transcription factors (OCT4 and KLF4) or one transcription factor (OCT4) 8 . However, NSCs are usually rare and difficult to access, representing a complicated target for reprogramming. Recently, the possibility of reprogramming blood cells to pluripotency has suggested an alternative source of somatic cells to generate iPSC. In particular, iPSC have been generated from mobilized peripheral blood (mPB) 4 or bone marrow (BM) 5 CD34 + derived cells by ectopic expression of OCT4, SOX2, KLF4 and c-MYC. Although these cells are certainly an accessible and widely used source, they may have accumulated genomic alterations as a result of aging or disease, and the isolation of hematopoietic stem cells could represent a health risk for the donor 9 .
Cord blood (CB) stem cells, currently widely used as a source of hematopoietic stem cells for transplantation, could overcome these problems. The main practical advantages of using CB stem cells are the relative ease of procurement, the absence of risks for the donors and the ability to store fully tested and HLA-typed samples in public banks 10 , available for immediate use. Another relevant consideration is that CB cells are young and are expected to carry minimal somatic mutations 11 .
We have demonstrated that CB CD133 + cells can be reprogrammed to pluripotency faster than fibroblasts and keratinocytes by ectopic expression of only two transcription factors (OCT4 and SOX2) 12 . CB CD133 + cells express a subset of pluripotency-associated genes (OCT4, SOX2, NANOG and CRIPTO), albeit at much lower levels than human ES cells (hESCs) (data not shown). On the other hand, the endogenous levels of c-MYC and KLF4 are higher in CB CD133 + cells compared with fibroblasts and keratinocytes (Fig. 1) . The combination of low levels of pluripotency markers with the high levels of KLF4 and c-MYC may allow for enhanced reprogramming of CB CD133 + cells. Cord blood iPS (CBiPS) cells are generated with only two factors offer new possibilities for investigating the molecular mechanisms that underline reprogramming to pluripotency.
Furthermore, and from a more practical point of view, CB cells could represent, in the future, an alternative, safer source of iPSC amenable to worldwide banking and distribution.
Here, we present a detailed protocol for the derivation of CB CD133 + cells and how to reprogram them to pluripotency by retroviral transfection of OCT4 and SOX2 in 2 weeks without the need for additional chemical compounds.
Experimental design
Derivation of CB CD133 + cells. Our protocol first focuses on the importance of selecting the correct cell subpopulation, within CB, for reprogramming. CD133 antigen is known as a stem cell marker for hematopoietic stem and progenitor cells. In contrast to CD34, the most widely used marker for hematopoietic stem cells (HSC) enrichment, CD133 is not found in late progenitors, providing a selection of a more homogeneous population enriched in HSC. CD133 + cells, which represent a small fraction of total nucleated cells in human CB (0.1-0.5%), are positively selected using the standard immunomagnetic separation system.
Generation of induced pluripotent stem cells from human cord blood cells with only two factors: Oct4 and Sox2
Induced pluripotent stem cells (ipsc) provide an invaluable resource for regenerative medicine as they allow the generation of patient-specific progenitors with potential value for cell therapy. However, in many instances, an off-the-shelf approach is desirable, such as for cell therapy of acute conditions or when the patient's somatic cells are altered as a consequence of a chronic disease or aging. cord blood (cB) stem cells appear ideally suited for this purpose as they are young cells expected to carry minimal somatic mutations and possess the immunological immaturity of newborn cells; additionally, several hundred thousand immunotyped cB units are readily available through a worldwide network of cB banks. Here we present a detailed protocol for the derivation of cB stem cells and how they can be reprogrammed to pluripotency by retroviral transduction with only two factors (oct4 and soX2) in 2 weeks and without the need for additional chemical compounds.
Retrovirus production. We produce retroviral vectors using the Phoenix Amphotropic packaging cell line. Retroviral vectors based on the Moloney murine leukemia virus (MuLV) have been extensively used as the primary tool for gene delivery into hematopoietic cells; however, they have also shown low transduction efficiencies. We could improve the gene transfer of MuLV-based vectors into CD133 + cells using a retronectin-facilitated protocol.
Transduction of CD133 + cells. The standard protocol used for fibroblast reprogramming needs to be modified for the transduction of CD133 + cells, which are in a quiescent state and grow in suspension. First, because the integration and expression of retroviral constructs requires mitotic division of the target cells, it is important to culture the CD133 + cells in vitro in the presence of SCF, Flt3-ligand, TPO and IL-6 cytokines for 24 h. Second, to increase the transduction efficiency, CD133 + cells are seeded over retronectin-coated plates pre-absorbed with the viral particles. CD133 + cells are infected three times every 12 h; on day 3 post-infection, cells are transferred to 6-well plates containing irradiated human fibroblasts (HFF) and hES medium and cultured until iPS colonies appear.
CBiPS cells.
As early as 9 d post-transduction with OCT4 and SOX2 (OS), small colonies start to appear, and after 15 d, some of the colonies exhibit a typical hESC morphology. penicillin-streptomycin (100 U ml − 1 , 100 µg ml − 1 ). To prepare 500 ml of medium, remove 60 ml of DMEM from a new bottle and add 50 ml FBS, 5 ml GlutaMax and 5 ml penicillin-streptomycin. Store at 4 °C in the dark and use within 2-3 weeks. bFGF Spin the lyophilized bFGF vial briefly to bring the contents down. Prepare HSA 0.2% in PBS in a sterile tube (1:50 dilution): 9.8 ml PBS + 0.2 ml HSA. Dissolve bFGF with PBS at 0.2% HSA to obtain a final concentration of 100 µg ml − 1 . Make 50 µl aliquots in screw-cap microcentrifuge tubes and store at − 20 °C.
MaterIals

REAGENTS
SCF, IL-6, TPO and Flt-3 ligand Centrifuge the lyophilized SCF, IL-6, TPO and Flt-3 ligand vials for 1 min so that all the content will fall down to the bottom. Prepare HSA 0.2% in PBS in a sterile tube (1:50 dilution). Dissolve SCF, IL-6, TPO and Flt-3 ligand with PBS 0.2% HSA to obtain a final concentration of 5 ng ml − 1 . Prepare 50 µl aliquots in screw-cap microcentrifuge tubes. Store at − 20 °C. hES cell medium To prepare 500 ml of hES medium, mix 387.5 ml of KO-DMEM with 100 ml of KOSR, 5 ml of Glutamax (1 mM), 5 ml of penicillin-streptomycin, 5 ml of nonessential amino acids (100 µM), 500 µl of 2-mercaptoethanol (100 µM) and 50 µl of bFGF (10 ng ml − 1 ). Filter the medium with a bottle-top 0.22-µm filter and store at 4 °C (maximum 1 week). Gelatin-coated culture dishes Add 0.1% gelatin solution to cover the bottom of the dish. Incubate the dish for at least 30 min at 37 °C. Aspirate and leave to dry for at least 10 min in the tissue culture hood. Use immediately. proceDure umbilical cB collection • tIMInG ~5 min 1| Collect umbilical CB into an integral plastic blood collection bag by venipucture (Fig. 2a) .  crItIcal step Patients' informed consents must be obtained before the delivery.  crItIcal step The CB should be stored at 4 °C during the transport and before separation. Processing of the CB should be carried out as quickly as possible to prevent the blood hemolysis or coagulum formation. Do not use samples older than 15 h.
Retroviral vectors
Isolation of umbilical cB mononuclear cells using lympholyte-H density gradient
• tIMInG ~2 h 2| All subsequent steps should be carried out in a tissue culture hood. Dilute the CB 1:3 with sterile PBS-EDTA in a sterile 500-ml bottle.
3| Layer 35 ml of diluted blood slowly on 15 ml of Lympholyte-H layer (ratio 3:1) in a 50-ml tube (Fig. 2b) .  crItIcal step Do not mix the tube; make sure the layers are not disturbed.
4|
Centrifuge for 25 min at 400g at room temperature (20-22 °C).  crItIcal step Acceleration and deceleration should be kept at speeds as low as possible to avoid any disturbance to cells in the white layer (Fig. 2c) .
5|
Collect the interphase cells (white layer) in a 50-ml tube using a plastic pipette.  crItIcal step Some cells might attach to the side of the tube in the form of a pellet; 'rub' them gently using the end of the pipette and collect them.
6|
Dilute the cell suspension with PBS-EDTA (ratio 1:1) and centrifuge for 5 min at 300g at room temperature.
7|
Pipette off the supernatant and pull together the pellets, resuspending the pellets in 50 ml of PBS-EDTA.
8|
Count the total number of mononuclear cells using a hematocytometer and asses the viability using Trypan Blue exclusion method (as described in Box 1). 
17|
Resuspend cell pellet in 500 µl of PBS-EDTA per 10 8 total cells and proceed to magnetic separation.
18|
Use one MS column up to 10 7 magnetically labeled cells or up to 2 × 10 8 total cells.  crItIcal step When working with larger cell numbers, divide the cell suspensions using two MS columns.
19|
Place the column in the magnetic field of the MACS Separator and place a 15-ml tube under the column. Rinse the column with 500 µl of PBS-EDTA.
20|
Apply 500 µl cell suspension onto the column and allow the negative cells to pass through.  crItIcal step Avoid forming bubbles/foam that can disturb migration of cells through the column.
21|
Wash the column twice with 500 µl PBS-EDTA.
22|
Remove the column from separator and place the column on a new collection 15-ml tube.
23| Pipette 1 ml of PBS-EDTA onto the column and firmly flash out the cell fraction magnetically labeled using the plunger.
24|
Repeat magnetic separation Steps 19-23. Apply the eluted cells to a new pre-filled column.
BOx 1 | CELL COUNTING
The following steps are used to count the total number of mononuclear cells in 10 µl of cell suspension: 1. Place 10 µl of mononuclear cell suspension in an appropriate tube containing 90 µl of Trypan Blue and mix gently. ), IL-6 (10 ng ml − 1 ) and TPO (10 ng ml − 1 ) in a 6-well plate. Incubate at 37 °C, 5% CO 2 for 24 h.  crItIcal step As the integration and expression of retroviral constructs require mitotic division of the target cells, it is important to carry out a pre-stimulation step of 24 h to induce the quiescent CD133 + cells to enter in a proliferative status.
retrovirus production • tIMInG ~1 week 28| Defrost a vial of Phoenix Amphotropic 293 cells (for details see Box 3). If using other virus or production approaches, jump to
Step 42. ! cautIon Use Category 2 (or higher) tissue culture hoods and exercise due caution in the production, storage and use of recombinant retroviral particles.
29|
Plate ~2 × 10 6 cells in complete DMEM medium in 100-mm tissue culture dish and incubate at 37 °C, 5% CO 2 for 2 d.
30|
When the cells reach 80% confluence (1-2 d), aspirate medium, wash gently with PBS, aspirate and add 3 ml 0.05% Trypsin-EDTA. Incubate for 1 min at 37 °C. Gently tap the tissue culture plate ensuring all cells are in suspension.
31| Add 10 ml complete DMEM medium to the plate, collect cell suspension and transfer to a 50-ml tube.
32|
Centrifuge at 200g for 5 min at room temperature.
33|
Resuspend pellet in 10 ml complete DMEM medium and count cells (as described in Box 1).
34| Plate 4 × 10 6 cells in 10 ml final volume in 100-mm culture dishes and place in a 37 °C, 5% CO 2 incubator.
35|
The next day, co-transfect Phoenix Amphotropic 293 cells with FuGENE-DNA complex according to the manufacturer's instructions. Briefly, place 0.873 ml of OPTIMEM into separate 1.5-ml tube (one for each of the plasmids to be transfected) and add 27 µl of FuGENE 6 transfection reagent, gently tapping the tube to mix. Next incubate at
BOx 2 | FLOW CYTOMETRY ANALYSIS
Flow cytometry analysis provides information about the purity of isolated CD133 + cells. 
36|
Add the FuGENE-DNA solution dropwise onto plate and return to a 37 °C, 5% CO 2 incubator overnight.  crItIcal step Gently add FuGENE-DNA complex solution dropwise. Phoenix Amphotropic 293 cells get detached easily from the plate if L-polylysine coating is not carried out.
37|
Next day, change the media gently (10 ml per plate) and incubate overnight in a 32 °C, 5% CO 2 incubator. If desired check transfection efficiency (see Fig. 3 ).  crItIcal step Virus is more stable at 32 °C, resulting in higher infectivity, although 37 °C is acceptable.  crItIcal step At this time point, near 100% confluence of cells should be transfected. Monitor transfection efficiency by using preferred GFP reporter plasmid (Fig. 3a,b) . 38| Collect 5 ml viral supernatant from every plate 48 h after transfection using plastic pipettes and filter the supernatant through a 0.45-µm PVDF filter to remove any residual cells.  crItIcal step Use low protein-binding filters to avoid trapping the virus and reducing the titer.  pause poInt Virus can be snap-frozen in cryovials using liquid nitrogen and stored at − 80 °C or in liquid nitrogen for several months. We have observed some loss in infectivity upon freezing.
39|
Add fresh 5 ml of complete DMEM to every plate and place in a 37 °C, 5% CO 2 incubator.  crItIcal step Take care to avoid cells detaching from the tissue culture plates.
40| Add 1 µl (10 mg ml − 1 ) of polybrene for each ml viral supernatant needed.
41| Every 12 h repeat Steps 38-40 to collect more viral supernatant. Collect twice more. Continue with Step 42 while carrying out these collections. retroviral transduction of cD133 + cells • tIMInG ~2d 42| Infection day 1: dispense an appropriate volume of retronectin solution (15 µg cm − 2 ) into each well of a 24-well plate and incubate for 2 h at room temperature.  crItIcal step We recommend diluting the retronectin solution in PBS and dispensing 500 µl of diluted retronectin into each well of a 24-well plate.
43|
Remove retronectin solution and add 500 µl of PBS containing 2% HSA (vol/vol) into each well for blocking.
44|
Incubate the plate for 30 min at room temperature.
45|
Remove the PBS-HSA solution and wash once with PBS.
46| Pre-load the viral supernatant derived from Phoenix Amphotropic 293 cells that have been filtered onto retronectincoated plates. Use equal amounts of each transcription factor to reach a total volume of 1 ml (500 µl for OCT4 and 500 µl for SOX2). 47| Set the plate into a centrifuge pre-warmed to 32 °C and centrifuge for 1 h at 2,000g at 32 °C.  crItIcal step If the titer of viral vector is high enough, then incubate for 4-6 h in a 32 °C, 5% CO 2 incubator. Centrifugation increases infectivity when the viral titer is low.
48| During centrifugation collect the CD133 + cells from
Step 27 in a 15-ml tube and count the number of living cells (as describe Box 1).
49|
Centrifuge for 5 min at 200g at room temperature.
50|
Suspend the pellet cells in complete DMEM medium supplemented with cytokines (SCF, Flt-3, IL-6 and TPO) at a concentration of 8 × 10 4 cells per ml.
51|
Pipette off the viral supernatant from each well, taking care that the virus bound to the retronectin does not dry out, and wash each well with 1 ml of PBS.
52|
Pipette off PBS and immediately add 1 ml of cell suspension into each well.
53|
Incubate for 12 h in a 37 °C, 5% CO 2 incubator.
54|
Infection day 2: repeat Steps 38-40.
55|
Remove 500 µl from each well of the 24-well plates containing CD133 + cells and add 500 µl of fresh viral supernatant to infect the cells a second time.  crItIcal step It is important to add the cytokine cocktail described in Step 27 (half the amount) to the fresh viral supernatant to keep the cells alive and proliferating (Fig. 4a) .
56|
57|
Repeat Steps 55 and 56 to infect the cells a third time and incubate for 24 h in a 37 °C, 5% CO 2 incubator.  crItIcal step We have noticed that infection efficiency, monitored by a constitutive GFP reporter retrovirus, can vary (10-40%).
? trouBlesHootInG culturing transduced cD133 + cells • tIMInG ~2 weeks 58| Plate the HFF in a gelatin-treated 6-well plate.
59|
Collect the cells in a 15-ml tube 1 d after the last infection.
60| Centrifuge for 5 min at 200g at room temperature.
61|
Resuspend in 1 ml hES medium and plate the infected CD133 + cells onto a 6-well plate containing HFF feeder and 1 ml of hES medium. aspirate the medium gently using a 1-ml pipette and to add fresh medium dropwise to prevent the few cells attached to the feeder from coming off (Fig. 4b) .
63| After 9 d small colonies start to appear. At 15 d of culture the colonies exhibit typical hESC morphology (Fig. 5a,b) .
picking and expanding ips cell colonies • tIMInG ~9 d 64| Day 1: identify colonies of iPS-like morphology and mark them on the bottom of the dish under the inverted microscope.
65|
Prepare the required number of 6-well plates with irradiated HFF feeder layers, calculating 1-well per colony to be picked.
66|
Day 2: aspirate the medium and add 2 ml of fresh hES medium in each well of the reprogramming dishes and 6-well feeder plates.
67|
Place the plate in a 37 °C, 5% CO 2 incubator for 20 min.
68|
Working on the stereomicroscope placed inside a tissue culture hood, manually pick the single colonies from each well using a stripper micropipette. Transfer colony fragments into a well with an HFF feeder. Incubate in a 37 °C, 5% CO 2 incubator.  crItIcal step To avoid cross-contamination with colonies originated in the same well, pick each colony with a new micropipette.
69|
Day 4: change the medium in each well. Many colony fragments should be attached to the feeder.
70|
Days 5-9: change the medium daily. Attached colony fragments will form iPS-like colonies, ready to be passaged by days 8-9.
Freezing of ips cells • tIMInG ~1 h 71|
Aspirate the medium and add 2 ml of fresh hES medium in each well.
72|
Pick approximately 20 colonies from each well and transfer the cell suspension in a 15-ml tube containing 2 ml pre-warmed hES medium. Centrifuge for 1 min at 200g at room temperature and aspirate the supernatant.
73| Drop-by-drop, add 1 ml of freezing medium and transfer the cells into freezing vial.
74|
Keep the vials in a cell-freezing container overnight at − 80 °C and then transfer them into a liquid nitrogen tank the next day. ! cautIon Liquid nitrogen is dangerous; use special protective clothing.
• tIMInG
Step 1, Umbilical CB collection: ~5 min CD133 + cells, with a purity range of 90-94%) (Fig. 6a) . On average, 8 × 10 4 CD133 + cells seeded over retronectin-coated plates previously pre-absorbed with viral particles (Fig. 4) and infected with OS give rise to five iPS colonies in 12-15 d. CBiPS colonies exhibited typical hESC morphology with sharp borders and small, tightly packed cell population with large nuclei (Fig. 5) . CBiPS cells show a differential potential similar to hESC in vitro, and when injected into immunocompromised SCID mice, CBiPS cells generate complex intratesticular teratomas, comprising structures and tissue derived from the three embryonic germ layers (Fig. 6b,c) . In addition, CBiPS cells show a genome-wide transcriptional profile similar to hESC and other iPS cell lines (Fig. 6d) 12 . 
